CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-18 | Sinha Vikas Director | Grant or award | +48,838 | 907,795 | ||
| 2022-01-18 | Sinha Vikas Director | Grant or award · Stock Option (Right to Buy) | +119,162 | 119,162 | ||
| 2022-01-18 | Atillasoy Ercem | Grant or award | +23,256 | 123,603 | ||
| 2022-01-18 | Atillasoy Ercem | Grant or award · Stock Option (Right to Buy) | +56,744 | 56,744 | ||
| 2022-01-18 | Miller Edward General Counsel | Grant or award | +23,256 | 217,307 | ||
| 2022-01-18 | Miller Edward General Counsel | Grant or award · Stock Option (Right to Buy) | +56,744 | 56,744 | ||
| 2022-01-18 | Brainard Diana Chief Executive Officer | Grant or award | +315,000 | 521,300 | ||
| 2022-01-18 | Brainard Diana Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +585,000 | 585,000 | ||
| 2022-01-18 | VAN BEEK JEROEN B Chief Commercial Officer | Grant or award | +23,256 | 405,640 | ||
| 2022-01-18 | VAN BEEK JEROEN B Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +56,744 | 56,744 | ||
| 2021-12-02 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −514 | $17.06 | $9K | 402,878 |
| 2021-11-16 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −15,203 | $21.13 | $321K | 403,392 |
| 2021-11-16 | Leen Ann M. Chief Scientific Officer | Sale | −100 | $21.76 | $2K | 2,288,154 |
| 2021-11-15 | Leen Ann M. Chief Scientific Officer | Sale | −6,122 | $21.92 | $134K | 2,288,254 |
| 2021-11-12 | Leen Ann M. Chief Scientific Officer | Sale | −14,266 | $22.26 | $318K | 2,294,876 |
| 2021-11-12 | Leen Ann M. Chief Scientific Officer | Sale | −500 | $23.18 | $12K | 2,294,376 |
| 2021-11-10 | Jovan-Embiricos Morana Director | Sale | −680 | $24.77 | $17K | 1,375,262 |
| 2021-11-10 | Jovan-Embiricos Morana Director | Sale | −120 | $24.77 | $3K | 342,693 |
| 2021-11-09 | Jovan-Embiricos Morana Director | Sale | −3,243 | $24.79 | $80K | 1,375,942 |
| 2021-11-09 | Jovan-Embiricos Morana Director | Sale | −572 | $24.79 | $14K | 342,813 |
Page 16 of 27 · 527 trades